Advertisement

Surgery in Brain Metastasis Management: Therapeutic, Diagnostic, and Strategic Considerations

  • Philippe Metellus
  • Johan Pallud
  • Zvi Ram
  • Colin Watts
  • Manfred Westphal
Chapter

Abstract

The incidence of brain metastases (BM) is increasing to date, mostly due to the actual improvement of cancer patient overall survival (OS) with the advent of targeted therapies. BM management has dramatically evolved over the last 15 years and uses varying strategies including more or less aggressive local treatments, sometimes combined with systemic therapies that led to an improvement of patient’s survival and quality of life. Surgical resection of BM has been shown to be an effective treatment improving overall survival compared to whole brain radiotherapy alone in patients with solitary brain metastasis. Brain metastases resection in patients with oligo metastatic disease especially for large symptomatic lesions with mass effect represent the standard of care. However, surgical resection alone is insufficient to provide a durable local control and recurrence in the surgical bed is common. Recent studies indicate local control could be improved through modern surgical techniques such as neuronavigation, brain mapping, and fluorescence guided surgery. Also, there is a growing body of evidence that molecular documentation of the brain metastatic disease could help to better define the systemic treatment strategy in these patients. Here, we reviewed evidence-based data available in the literature on the actual prognostic impact of surgery in BM patients and provided an overview of new surgical techniques and adjuncts that may improve surgical resection. Finally, we discussed the actual role of the neurosurgeon in the global treatment strategy and management in these BM patients.

Keywords

Brain metastases (BM) Surgery Stereotactic radiotherapy (SRT) Radiosurgery Tumor biology 

References

  1. 1.
    Mehta MP, Khuntia D. Current strategies in whole-brain radiation therapy for brain metastases. Neurosurgery. 2005;57(5 Suppl):S33-44; discusssion S1-4.CrossRefGoogle Scholar
  2. 2.
    Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2005;63(1):37–46.CrossRefGoogle Scholar
  3. 3.
    Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010;96(1):17–32.CrossRefGoogle Scholar
  4. 4.
    Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010;96(1):33–43.CrossRefGoogle Scholar
  5. 5.
    Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010;96(1):45–68.CrossRefGoogle Scholar
  6. 6.
    Al-Shamy G, Sawaya R. Management of brain metastases: the indispensable role of surgery. J. Neurooncol. 2009;92(3):275–82.CrossRefGoogle Scholar
  7. 7.
    Lang FF, Sawaya R. Surgical management of cerebral metastases. Neurosurg. Clin. N. Am. 1996;7(3):459–84.CrossRefGoogle Scholar
  8. 8.
    Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990;322(8):494–500.CrossRefGoogle Scholar
  9. 9.
    Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann. Neurol. 1993;33(6):583–90.CrossRefGoogle Scholar
  10. 10.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.CrossRefGoogle Scholar
  11. 11.
    Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 1997;37(4):745–51.CrossRefGoogle Scholar
  12. 12.
    Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470–6.CrossRefGoogle Scholar
  13. 13.
    Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.Google Scholar
  14. 14.
    Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011;29(2):134–41.CrossRefGoogle Scholar
  15. 15.
    Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013;31(1):65–72.CrossRefGoogle Scholar
  16. 16.
    Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9.CrossRefGoogle Scholar
  17. 17.
    Roberge D, Parney I, Brown PD. Radiosurgery to the postoperative surgical cavity: who needs evidence? Int. J. Radiat. Oncol. Biol. Phys. 2012;83(2):486–93.CrossRefGoogle Scholar
  18. 18.
    Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–8.CrossRefGoogle Scholar
  19. 19.
    Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–60.CrossRefGoogle Scholar
  20. 20.
    Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J. Neurosurg. 1993;79(2):210–6.CrossRefGoogle Scholar
  21. 21.
    Bindal RK, Sawaya R, Leavens ME, Hess KR, Taylor SH. Reoperation for recurrent metastatic brain tumors. J. Neurosurg. 1995;83(4):600–4.CrossRefGoogle Scholar
  22. 22.
    Le Tourneau C, Kamal M, Tredan O, Delord JP, Campone M, Goncalves A, et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target. Oncol. 2012;7(4):253–65.CrossRefGoogle Scholar
  23. 23.
    Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, et al. Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. 2017;3(5):666–71.CrossRefGoogle Scholar
  24. 24.
    Metellus P, Bialecki E, Le Rhun E, Dhermain F. Neurosurgical and radiosurgical decision making in brain metastasis patients in the area of targeted therapies? Chin. Clin. Oncol. 2015;4(2):19.Google Scholar
  25. 25.
    Metellus P, Tallet A, Dhermain F, Reyns N, Carpentier A, Spano JP, et al. Global brain metastases management strategy: a multidisciplinary-based approach. Cancer Radiother. 2015;19(1):61–5.CrossRefGoogle Scholar
  26. 26.
    Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res. Treat. 2011;129(3):659–74.CrossRefGoogle Scholar
  27. 27.
    Duchnowska R, Jassem J, Goswami CP, Dundar M, Gokmen-Polar Y, Li L, et al. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J. Neurooncol. 2015;122(1):205–16.CrossRefGoogle Scholar
  28. 28.
    Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, et al. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol. 2015;17(9):1241–9.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Duchnowska R, Peksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016;18(1):43.CrossRefGoogle Scholar
  30. 30.
    Duchnowska R, Jarzab M, Zebracka-Gala J, Matkowski R, Kowalczyk A, Radecka B, et al. Brain metastasis prediction by transcriptomic profiling in triple-negative breast cancer. Clin. Breast Cancer. 2017;17(2):e65–75.CrossRefGoogle Scholar
  31. 31.
    Vareslija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O’Halloran PJ, et al. Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets. J. Natl. Cancer Inst. 2019;111(4):388–98.CrossRefGoogle Scholar
  32. 32.
    Lee JY, Park K, Lim SH, Kim HS, Yoo KH, Jung KS, et al. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget. 2015;6(41):43731–42.CrossRefGoogle Scholar
  33. 33.
    Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164–77.CrossRefGoogle Scholar
  34. 34.
    Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–34.CrossRefGoogle Scholar
  35. 35.
    Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, Salomon MP, Barkhoudarian G, Jalas JR, et al. Epigenetic profiling for the molecular classification of metastatic brain tumors. Nat. Commun. 2018;9(1):4627.CrossRefGoogle Scholar
  36. 36.
    De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, et al. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget. 2018;9(29):20617–30.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Tyran M, Carbuccia N, Garnier S, Guille A, Adelaide J, Finetti P, et al. A Comparison of DNA mutation and copy number profiles of primary breast cancers and paired brain metastases for identifying clinically relevant genetic alterations in brain metastases. Cancers (Basel). 2019;11(5).CrossRefGoogle Scholar
  38. 38.
    Schulten HJ, Bangash M, Karim S, Dallol A, Hussein D, Merdad A, et al. Comprehensive molecular biomarker identification in breast cancer brain metastases. J. Transl. Med. 2017;15(1):269.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Philippe Metellus
    • 1
    • 2
  • Johan Pallud
    • 3
    • 4
    • 5
  • Zvi Ram
    • 6
    • 7
  • Colin Watts
    • 8
  • Manfred Westphal
    • 9
  1. 1.Department of Neurosurgery and Neuro-OncologyClairval Hospital Center, Ramsay-Générale de SantéMarseilleFrance
  2. 2.Neurophysiopathology Institute, Aix-Marseille UniversitéMarseilleFrance
  3. 3.Department of NeurosurgerySainte-Anne HospitalParisFrance
  4. 4.Paris Descartes University, Sorbonne Paris CitéParisFrance
  5. 5.Inserm, U894, IMABrain, Institute of Psychiatry and Neurosciences of ParisParisFrance
  6. 6.Department of NeurosurgeryTel Aviv Medical CenterTel-AvivIsrael
  7. 7.Tel Aviv UniversityTel AvivIsrael
  8. 8.Institute of Cancer and Genomic Sciences, University of BirminghamBirminghamUK
  9. 9.Department of NeurosurgeryUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations